Early initiation of inhaled corticosteroid–long‐acting β 2 ‐agonist therapy and reduction of severe asthma exacerbations in high‐risk preschool children: A longitudinal real‐world cohort study
Pediatric Allergy and Immunology · 2026
DOI: 10.1111/pai.70411 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pediatric Allergy and Immunology, 2026. Verfasst von Arthur H Owora und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapol…. Hauptthemen laut MEDLINE: Asthma, Adrenal Cortex Hormones, Adrenergic beta-2 Receptor Agonists, Anti-Asthmatic Agents. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Evidence supporting inhaled corticosteroid plus long‐acting β 2 ‐agonist (ICS + LABA) therapy in preschool children with asthma remains limited, and guideline recommendations remain cautious. However, real‐world effectiveness in high‐risk young children has not been adequately characterized.
Objective
To evaluate short‐ and long‐term effectiveness of ICS + LABA initiation on severe asthma exacerbations (SAEs) and determine whether early‐life asthma risk burden modifies treatment response.
Methods
We conducted a retrospective longitudinal cohort study using electronic health record data from the Indiana Network for Patient Care (2010–2024). Children aged ≤11 years with asthma who initiated ICS + LABA between 2010 and 2023 and had ≥12 months of pre‐ and post‐initiation follow‐up were included. The primary outcome was ≥1 SAE per year, defined per ATS/ERS criteria as asthma‐related hospitalization or emergency department admission. Piecewise generalized linear mixed‐effects models estimated annualized changes in SAE odds before versus after ICS + LABA initiation. Recurrent events were analyzed using Andersen–Gill models. Effect modification by age at diagnosis, age at prior ICS initiation, and early‐life asthma risk burden (passive digital marker [PDM] score) was assessed.
Results
Among 249 children (mean age at asthma diagnosis 2 years; at ICS + LABA initiation 5 years), annualized SAE incidence increased before initiation and declined thereafter. Adjusted SAE odds decreased by 15% per year following ICS + LABA initiation (aOR 0.85; 95% CI 0.58–0.98). Recurrent‐event modeling demonstrated a 68% reduction in SAE hazard after ICS + LABA initiation (aHR 0.32; 95% CI 0.26–0.38), exceeding reductions observed with ICS alone (aHR 0.49). Treatment benefit was greatest among children initiating ICS before age 5 years (aOR 0.77; 95% CI 0.65–0.92) and those with high early‐life asthma risk burden (aOR 0.80; 95% CI 0.67‐0.97). No significant heterogeneity was observed by sex, race, or formulation.
Conclusions
ICS + LABA initiation was associated with sustained reductions in severe exacerbations, including among preschool children, in real‐world clinical practice. These findings suggest that strict age‐based treatment restrictions may not fully capture heterogeneity in exacerbation risk and support further prospective evaluation of risk‐stratified escalation strategies. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
ORCID-Profile: Arthur H Owora
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Owora, A. H., Jiang, B., & Shah, Y. (2026). Early initiation of inhaled corticosteroid–long‐acting β 2 ‐agonist therapy and reduction of severe asthma exacerbations in high‐risk preschool children: A longitudinal real‐world cohort study. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70411
Vancouver
Owora AH, Jiang B, Shah Y. Early initiation of inhaled corticosteroid–long‐acting β 2 ‐agonist therapy and reduction of severe asthma exacerbations in high‐risk preschool children: A longitudinal real‐world cohort study. Pediatric Allergy and Immunology. 2026. doi:10.1111/pai.70411
BibTeX
@article{Owora2026,
author = {Owora, Arthur H and Jiang, Bowen and Shah, Yash},
title = {Early initiation of inhaled corticosteroid–long‐acting β 2 ‐agonist therapy and reduction of severe asthma exacerbations in high‐risk preschool children: A longitudinal real‐world cohort study},
journal = {Pediatric Allergy and Immunology},
year = {2026},
doi = {10.1111/pai.70411}
}
EUVIMED